GlassScriptPhysician profile
Bobby S Alexander
NPI 1235575903
$4,235.75
in general payments reported to CMS, 2019-2025
33 companies · $270 in 2025
The $270 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $476 · 2021: $357 · 2022: $220 · 2023: $1,548 · 2024: $877 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,694.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $478.19 | 2023-2024 | Urolift |
| Biotissue Holdings INC. | $474.97 | 2022-2023 | |
| Abbott Laboratories | $471.44 | 2020-2025 | Proclaim |
| Boston Scientific Corporation | $370.23 | 2019-2022 | |
| Medtronic USA, INC. | $278.72 | 2019-2020 | |
| Urogen Pharma, INC. | $263.70 | 2022-2024 | |
| Telix Pharmaceuticals | $207.78 | 2022-2024 | Illuccix |
| Coloplast Corp | $189.18 | 2019-2025 | Speedicath |
| Palette Life Sciences, INC. | $173.48 | 2023 | |
| Sumitomo Pharma America, INC. | $160.67 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $149.81 | 2019-2024 | Veozah, Xtandi |
| Laborie Medical Technologies Corp. | $117.39 | 2020 | |
| Neotract INC. | $107.79 | 2019 | |
| Myriad Genetic Laboratories, INC. | $75.22 | 2023-2025 | Prolaris |
| Abbvie INC. | $67.49 | 2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $66.93 | 2019-2024 | Gentlecath Glide |
| Caldera Medical, INC | $66.87 | 2021 | |
| Janssen Biotech, INC. | $62.68 | 2019-2021 | |
| Axonics, INC. | $59.52 | 2023 | Axonics |
| Rochester Medical Corporation | $51.59 | 2022 | |
| Pfizer INC. | $44.79 | 2019-2025 | |
| Tolmar Pharmaceuticals, INC. | $41.74 | 2019-2021 | |
| Hollister Incorporated | $36.19 | 2021 | |
| Verity Pharmaceuticals INC. | $33.88 | 2025 | Trelstar |
| Dendreon Pharmaceuticals LLC | $27.33 | 2025 | Provenge |
| Blue Earth Diagnostics | $26.50 | 2023 | |
| Procept Biorobotics Corporation | $24.69 | 2023 | Aquabeam Robotic System |
| Therapeuticsmd, INC. | $23.87 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $23.19 | 2023 | Lynparza |
| Becton, Dickinson and Company | $22.32 | 2024 | Bard Urinary Drainage Bag |
| Immunitybio, INC. | $20.17 | 2024 | |
| Tolmar, INC. | $16.43 | 2023 | |
| Urocure LLC | $1.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobby Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.